Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer

Melinta Therapeutics today announced that John Temperato has joined Melinta as President and Chief Operating Officer. Prior to joining Melinta, John led the sales and managed markets division of Salix Pharmaceuticals, where he was responsible for growing the company’s revenues from growth from $119 million in 2004 to $2 billion in 2015. He played a critical role at Salix in the successful commercialization and growth of Xifaxan, a non-systemic antibiotic, for hepatic encephalopathy, traveler’s diarrhea, and irritable bowel syndrome.